drugset / Trial / NCT03097315

Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis

NCT03097315

Phase 3 Completed 38 enrolled Clearside Biomedical, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This open-label study is designed to evaluate the safety of suprachoroidally administered triamcinolone acetone injectable suspension, CLS-TA, in patients with non-infectious uveitis with and without macular edema.

Timeline

Start
2017-04-04
Primary completion
2018-01-24
Completion
2018-01-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Triamcinolone Acetonide Other / unclassified 4 mg Other